or Try an Advanced Search...

    Technical Analysis for ZURA - Zura Bio Limited

    Grade Last Price % Change Price Change
    B 4.41 21.82% 0.79
    ZURA closed up 21.82 percent on Friday, April 26, 2024, on 2.72 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical ZURA trend table...
    Date Alert Name Type % Chg
    Expansion Breakout Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Range Bar Range Expansion 0.00%
    Parabolic Rise Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Calm After Storm Range Contraction 21.82%
    Wide Bands Range Expansion 21.82%
    Gapped Up Strength 21.82%
    Older End-of-Day Signals for ZURA ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot about 10 hours ago
    3x Volume Pace about 15 hours ago
    60 Minute Opening Range Breakout about 15 hours ago
    Up 2 ATRs about 15 hours ago
    2x Volume Pace about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ZURA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody

    Is ZURA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
    Apr 18 Zura Bio stock jumps on plans to raise $112.5M in private financing
    Apr 18 Zura Bio Announces Oversubscribed $112.5 Million Private Placement
    Apr 8 Zura Bio names new executive chief
    Apr 8 Zura Bio Announces Robert Lisicki as CEO and Director
    Apr 2 Insider Buyers At Zura Bio Recover Some Losses, But Still Down US$165k
    Mar 28 Zura Bio GAAP EPS of -$2.09 beats by $0.53
    Mar 28 Zura Bio GAAP EPS of -$2.09
    Mar 28 Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
    Mar 4 Zura Bio Announces Participation at March Conferences
    See more ZURA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.0
    52 Week Low 2.0
    Average Volume 329,106
    200-Day Moving Average 4.83
    50-Day Moving Average 3.22
    20-Day Moving Average 3.17
    10-Day Moving Average 3.44
    Average True Range 0.44
    RSI (14) 69.70
    ADX 28.4
    +DI 39.99
    -DI 11.16
    Chandelier Exit (Long, 3 ATRs) 3.50
    Chandelier Exit (Short, 3 ATRs) 3.57
    Upper Bollinger Bands 3.97
    Lower Bollinger Band 2.36
    Percent B (%b) 1.27
    BandWidth 50.92
    MACD Line 0.19
    MACD Signal Line 0.06
    MACD Histogram 0.1298
    Fundamentals Value
    Market Cap 190.04 Million
    Num Shares 43.1 Million
    EPS 0.15
    Price-to-Earnings (P/E) Ratio 29.40
    Price-to-Sales 0.00
    Price-to-Book 2.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.14
    Resistance 3 (R3) 6.08 5.46 5.85
    Resistance 2 (R2) 5.46 5.02 5.48 5.75
    Resistance 1 (R1) 4.93 4.75 5.20 4.99 5.66
    Pivot Point 4.31 4.31 4.44 4.33 4.31
    Support 1 (S1) 3.78 3.87 4.05 3.84 3.16
    Support 2 (S2) 3.16 3.60 3.18 3.07
    Support 3 (S3) 2.63 3.16 2.97
    Support 4 (S4) 2.69